Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Running, not enrolling · Phase 1
Conditions studied: Lymphoid Leukemia
In brief
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.
Key facts
- Study ID
- NCT05507827
- Run by
- Stanford University
- People needed
- 22
- Starts
- 2022-08-18
- Expected to finish
- 2045-12-01
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Cancer Center — Palo Alto, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.